Bioventus Inc.BVSNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank92
5Y CAGR+1.9%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

5Y CAGR
+1.9%/yr
Long-term compound
Percentile
P92
Near historical high
vs 5Y Ago
1.1x
Modest growth
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM18.58%+171.6%
20246.84%+251.9%
2023-4.50%+81.0%
2022-23.75%-325.0%
202110.55%-37.6%
202016.91%-6.6%
201918.11%+6.0%
201817.08%-16.6%
201720.49%+27.7%
201616.05%-